Dr. Philip B. Gorelick is the John S. Garvin Professor and Head, Department of Neurology and Rehabilitation, and Director of Stroke Research at the University of Illinois College of Medicine at Chicago.
Dr Gorelick received his medical degree from the Cardinal Stritch School of Medicine at Loyola in 1977. He completed his Neurology Residency at Loyola and HINES VAH and then completed a fellowship in stroke under Louis Caplan. MD, at Michael Reese Hospital as part of the University of Chicago Neurology Program in 1982.
Dr. Gorelick is certified in Neurology and Vascular Neurology by the American Board of Psychiatry and Neurology.
Dr. Gorelick is well-known in national and international circles as a world leader in stroke prevention. He has developed innovative studies for identification of risk factors for stroke, prevention of first and recurrent stroke, and the elucidation of risk factors and mechanisms for vascular forms of cognitive impairment. His important work has been recognized by major stroke organizations worldwide as he has received the Feinberg Award for Excellence in Clinical Stroke from the American Heart Association and National Stroke Association Visionary in Stroke Award. He has served as the Chair of the International Stroke Conference, chaired or been a major participant in NIH progress or planning groups. He has published over 200 peer-reviewed articles and has edited six books in his field. He also holds the distinction of continuous funding from the NIH for his research work over an18-year period.
Gorelick PB. Cerebral microbleeds. Evidence of heightened risk associated with aspirin use. Arch Neurol 2009; 66(6): 691-693.
Gorelick PB. The burden and management of TIA and stroke in government-funded healthcare programs. Am J Manag Care 2009; 15: S177-S184.
Aiyagari V, Gorelick PB. Management of blood pressure for acute and recurrent stroke. Stroke 2009; 40: 2251-2256.
Schwamm LH...Gorelick PB. Recommendations for the implementation of telemedicine within stroke systems of care. Stroke 2009; 40: 2635-60.
Roberts CS, Gorelick PB..Additional stroke-related and non-stroke-related cardiovascular costs and hospitalizations in managed-care patients after ischemic stroke. Stroke 2009; 40: 1425-32.
Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, Vandermaelen C, Voigt T, Weber M, Yoon BW; the PRoFESS Study Group. Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke. N Engl J Med. 2008 Aug 27. [Epub ahead of print]
Gorelick PB. Primary prevention of stroke: impact of healthy lifestyle. Circulation. 2008 Aug 26;118(9):904-6.
Gorelick PB. Lipoprotein-associated phospholipase A2 and risk of stroke. Am J Cardiol. 2008 Jun 16;101(12A):34F-40F.
Gorelick PB, Wong KS, Bae HJ, Pandey DK. Large artery intracranial occlusive disease: a large worldwide burden but a relatively neglected frontier. Stroke. 2008 Aug;39(8):2396-9. Epub 2008 Jun 5.
Adams RJ, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick PB, Halperin J, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton EJ, Marks M, Sacco RL, Schwamm LH, American Heart Association, American Stroke Association. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2008 May;39(5):1647-52.